Skip to main content
VYGR
NASDAQ Life Sciences

Voyager Q3 Loss Narrows to $24.7M; $132.1M Cash Funds Operations Into Q2 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.69
Mkt Cap
$105.983M
52W Low
$1.675
52W High
$5.478
52W Position info
0.9% above low
Off High info
69% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

VYGR is trading near its 52-week low of $1.675 (0.9% above the low) on elevated volume (1.9× avg).

Summary

Voyager narrowed its Q3 2026 net loss to $24.7 million and held $132.1 million in cash and securities, enough to fund operations into the second quarter of 2028. Collaboration revenue fell to $4.0 million from $13.4 million a year earlier.


Key Events · Earnings and Guidance · VYGR

  • Q3 Loss Narrows on Cost Cuts

    Net loss was $24.7 million versus $27.9 million in Q3 2025; R&D fell to $24.4 million from $35.9 million and G&A to $6.1 million from $8.1 million.

  • Cash Runway Into Q2 2028

    Cash, cash equivalents and marketable securities totaled $132.1 million at September 30, 2026, down from $191.0 million at December 31, 2025; management projects funding into the second quarter of 2028.

  • Collaboration Revenue Declines

    Revenue fell to $4.0 million from $13.4 million in Q3 2025 and to $9.8 million from $25.0 million for the nine months, driven by lower Neurocrine revenue recognition.

  • ATM Drip-Feeds $8.7M

    Sold 2,236,872 shares under the $100.0 million ATM Facility at a weighted-average price of $4.00 for net proceeds of $8.7 million; $91.0 million remains available.


Analysis · VYGR · Life Sciences

Cost control is the story here: Voyager's quarterly loss narrowed to $24.7 million from $27.9 million a year ago, helped by restructuring and program prioritization that cut R&D to $24.4 million from $35.9 million. The company ended September with $132.1 million in cash and securities, down from $191.0 million at year-end, and says that funds operations into the second quarter of 2028 — roughly two and a half years of runway, which removes near-term financing pressure for a stock trading near its 52-week low. Collaboration revenue fell to $4.0 million from $13.4 million, so the story is cost control and runway rather than top-line growth. The next hard data point is initial tau PET efficacy data from the VY7523 Phase 1 MAD trial, expected in the fourth quarter of 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VYGR was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106M. The 52-week trading range was $1.68 to $5.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VYGR - Latest Insights

VYGR
Oct 21, 2026, 8:09 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.53 info
Change: -$0.620 (-29%) info
Market Cap: $95.211M info
VYGR
Oct 21, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.53 info
Change: -$0.620 (-29%) info
Market Cap: $95.211M info
VYGR
Jul 13, 2026, 8:44 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.54
Real-time Price: $1.53 info
Change: -$2.01 (-57%) info
Market Cap: $95.211M info
VYGR
Jul 13, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.45
Real-time Price: $1.53 info
Change: -$1.92 (-56%) info
Market Cap: $95.211M info
VYGR
Jun 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $1.53 info
Change: -$1.79 (-54%) info
Market Cap: $95.211M info